“…73 Study design may be the influence here, in that single case, validation or cohort studies may be delivered by the developer of the initiative in these reviewed articles. 31,39,52,74,75 This is akin to a pharmaceutical manufacturer not only paying for the research but also administering the drug to the patient, which implicates further bias. 76 The randomised trials within this review fared no better than lower quality designs in terms of reporting, although the single incidence of patient and practitioner satisfaction was an RCT of small sample size in a journal of low impact.…”